ESMO 2023 | The benefits of adjuvant CDK4/6 and PARP inhibition in breast cancer

Patrick Neven, MD, University Hospitals Leuven, Leuven, Belgium, comments on the role of adjuvant therapy for patients who have progressed on chemotherapy and endocrine therapy. The Phase III monarchE (NCT03155997) and NATALEE (NCT03701334) trials, which assessed adjuvant abemaciclib and ribociclib respectively, supports the use of adjuvant therapy in the HR+/HER2- setting. The OLYMPIA trial (NCT02032823) additionally shows the benefits of olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.